New Target Identified for Scleroderma Therapy

First Page		Document Content
Date: 2015-02-26 10:23:23 Mucinoses Connective tissue diseases Medicine Scleroderma Systemic scleroderma Autoimmunity Fibrosis Systemic Sclerosis Anatomy Health Autoimmune diseases		New Target Identified for Scleroderma Therapy Add to Reading List Source URL: phys.org Download Document from Source Website File Size: 27,31 KB Share Document on Facebook

	PRESS RELEASE Genkyotex’s GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis Geneva, Switzerland, and Archamps, France, 11th November, 2015 – Genkyotex, the leading de DocID: 1qCta - View Document
	Technology Opportunity, Ref. No. UZNovel Pharmacological Treatment of Scleroderma This invention relates to a novel pharmacological treatment of scleroderma comprising the administration of miR-29. DocID: 1pOlw - View Document
	Curriculum Vitae BIOGRAPHICAL Name: Janet L. Poole Birthplace: La Jolla, CA Citizenship: USA Business Address: DocID: 1prfA - View Document
	Privacy Policy* April, 2015 The Scleroderma Society of Canada is committed to protecting the privacy of the personal information of its employees, volunteers, members, customers, donors and other stakeholders. We value t DocID: 1af4J - View Document
	Soluble CD90 as biomarker of pulmonary complications in Systemic Sclerosis A new serological two-staged biomarker of pulmonaryarterial hypertension and pulmonary fibrosis Subtitle Technology DocID: 19Tlu - View Document